Michael Fischbach is the Liu (Liao) Family Professor of Bioengineering at Stanford University, an Institute Scholar of Stanford ChEM-H, and the director of the Stanford Microbiome Therapies Initiative.
Fischbach is a recipient of the NIH Director’s Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucile Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, and the Vannevar Bush Faculty Fellowship.
His laboratory studies the mechanisms of microbiome-host interactions. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in chemistry from Harvard in 2007, where he studied the role of iron acquisition in bacterial pathogenesis and the biosynthesis of antibiotics.
After two years as an independent fellow at Massachusetts General Hospital, Fischbach joined the faculty at UCSF, where he founded his lab before moving to Stanford in 2017.
Fischbach is a co-founder of Kelonia and Revolution Medicines, a member of the scientific advisory boards of the Chan Zuckerberg Initiative, NGM Biopharmaceuticals, Stand Up to Cancer, and TCG Labs/Soleil Labs, and an innovation partner at The Column Group.
